Free Trial

Brean Capital's Rating of Akebia Therapeutics on 9/29/2016

On September 29, 2016, Brean Capital updated its outlook on Akebia Therapeutics (NASDAQ:AKBA) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.